Overview

* EDAP TMS Q3 2025 revenue beats analyst expectations, driven by HIFU growth

* HIFU revenue increased 49% yr/yr, driven by Focal One sales and U.S. procedures

* Net loss for Q3 2025 was €5.0 mln, improved from €6.4 mln in Q3 2024

Outlook

* Company reiterates 2025 guidance: core HIFU revenue to grow 26%-34% YoY

* Non-core business revenue expected to decline 25%-30% YoY in 2025

* EDAP secures €36 mln credit facility to expand Focal One platform

Result Drivers

* HIFU GROWTH - 49% YoY revenue increase driven by Focal One sales and U.S. procedure volumes

* SYSTEM PLACEMENTS - 167% YoY growth in Focal One system placements

* PROCEDURE VOLUMES - 15% YoY growth in U.S. Focal One HIFU procedures

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat EUR EUR

Revenue 13.88 12.90

mln mln (3

Analysts

)

Q3 Net -EUR

Income 5.01 mln

Q3 Basic -EUR

EPS 0.13

Q3 Gross EUR 5.97

Profit mln

Q3 -EUR

Operatin 10.90

g mln

Expenses

Q3 -EUR

Operatin 4.93 mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

* Wall Street's median 12-month price target for Edap Tms SA ( EDAP ) is $1.80, about 15.6% below its November 5 closing price of $2.08

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)